The expected launch of Novartis’s new heart failure drug next year promises to be the company’s most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday. The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial. Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multibillion-dollar sales opportunity. “It will be possibly the most exciting launch the company has ever had,” David Epstein told an investor meeting.

The expected launch of Novartis’s new heart failure drug next year promises to be the company’s most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday. The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial. Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multibillion-dollar sales opportunity. “It will be possibly the most exciting launch the company has ever had,” David Epstein told an investor meeting.